Search

Objective This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax (ΔSUVmax [%]) in patients with axillary lymph node–positive breast cancer receiving neoadjuvant chemotherapy (NAC). Methods One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (ΔSUVmaxB) and axilla (ΔSUVmaxA) were measured. The optimal cut-off value of SUVmax and ΔSUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan–Meier curves. Results ΔSUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P Conclusion The results showed that ΔSUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node–positive breast cancer who received NAC.

Resumen Objetivo En este estudio, se tuvo como objetivo determinar el papel pronostico del valor de captacion maximo estandarizado (SUVmax) basal obtenido por PET/TC antes del tratamiento, y el cambio en el SUVmax (ΔSUVmax [%]) en pacientes con cancer de mama con ganglios linfaticos axilares positivos en tratamiento con quimioterapia neoadyuvante (NAC). Metodos Se evaluaron en el estudio 180 pacientes con SUVmax basal y 121 pacientes con medicion de SUVmax despues del tratamiento. Se midieron el valor de SUVmax inicial de la mama (SUVmaxBI) y axila (SUVmaxAI), y el cambio en el SUVmax de la mama (ΔSUVmaxB) y axila (ΔSUVmaxA). El valor de corte optimo de SUVmax y ΔSUVmax se determino mediante el analisis de la curva ROC. La supervivencia libre de enfermedad (SSE) y la supervivencia global (SG) se calcularon mediante curvas de Kaplan-Meier. Resultados Se encontro que los parametros ΔSUVmaxB, pCRB, pCRA y pCR se asociaron con la recaida (p Conclusion Los resultados muestran que ΔSUVmaxB es un factor pronostico independiente de recaida y mortalidad en pacientes con cancer de mama con ganglios linfaticos axilares positivos que recibieron NAC.

Cancer patients are among patient groups most affected by the COVID-19 outbreak. During the COVID-19 pandemic, rearrangement of oncological services and adaptation to the pandemic process has become mandatory. In this review, we mentioned the changes in medical oncology practice and adaptive treatment modifications. COVID-19 infection will continue to affect and change the practice of oncology unless the COVID-19 outbreak ends.

To investigate the status of thiol-disulphide homeostasis and ischemic-modified albumin and their association with clinicopathological parameters in breast cancer.A cross-sectional descriptive study.Department of Internal Medicine and Department of Medical Oncology, Dicle University, Turkey, from April to September 2021.Forty treatment-naive female patients diagnosed with breast cancer who presented to the Oncology Clinic of the hospital and 33 healthy women with no comorbidities were included. Serum levels of native thiol (NT), disulphide (Ds), total thiol (TT), IMA (ischemic modified albumin) at diagnosis and disulphide/native thiol (Ds/NT), disulphide/total thiol (Ds/TT), and the ratios of native thiol/total thiol (NT/TT) were analysed by the colorimetric method.Median age at diagnosis was 44 (29-70) years. The majority of patients had stage II-III disease (77.5%). Mean serum levels of TT were significantly lower in breast cancer patients (462.45 ± 100.2 μmol/L) compared to healthy controls (507.28 ± 75.72 μmol/L) (p=0.038). Mean serum levels of Ds were significantly lower in breast cancer patients (20.25 ± 5.94 μmol/L) compared to healthy controls (22.99 ± 3.56 μmol/L) (p=0.018). Meanwhile, mean IMA levels were significantly higher in breast cancer patients (0.81 ± 0.05 μmol/L) compared to healthy controls (0.73 ± 0.19 μmol/L) (p=0.016). NT and TT levels showed a moderate correlation with the percentage of fat mass and body mass index (BMI), and a weak correlation with age (p0.05). Univariate and multivariate analyses examining the association between thiol-disulphide levels and patient clinical characteristics demonstrated that NT and TT levels had a statistically significant relationship with body mass index and menopausal status (p0.05), with lower levels of NT and TT in postmenopausal patients and patients with high BMI.Decreased TT and Ds levels and increased IMA levels were determined in patients diagnosed with breast cancer compared to the healthy control group. Thiol-disulphide levels were observed to be associated with clinical characteristics such as menopausal status and BMI.Breast cancer, Thiol, Ischemic modified albumin.